Regulation of the expression of FGFR2IIIc isoform, a novel therapeutic strategy for cervical cancer

成纤维细胞生长因子受体2（FGFR2）被认为是FGFR2突变或基因扩增患者癌症治疗的分子靶点。在这项研究中，我们研究了FGFR 2的一种亚型FGFR 2IIIc在宫颈癌中的表达和作用。FGFR2IIIc在宫颈癌细胞中高表达。而且不仅ERK信号通路参与宫颈癌的发生发展，AKT信号通路也参与宫颈癌的发生发展。FGFR 2IIIc在子宫内膜病变中的表达与子宫颈病变的表达模式相同。提示FGFR 2IIIc在宫颈癌和类宫颈癌的发生发展中起重要作用。FGFR2IIIc有望成为子宫癌治疗的新靶点。

Fibroblast growth factor receptor 2(FGFR2) is noted as a molecular target for cancer treatment in patients with FGFR2 mutation or gene amplification. In this study, we investigated the expression and role of FGFR2IIIc, an isoform of FGFR2, in cervical carcinoma. The expression of FGFR2IIIc was highly detected in cervical cancer cells. And not only the ERK signaling pathway, but the AKT signaling pathway are involved in the progression of cervical carcinoma. Furthermore, the expression of FGFR2IIIc in endometrial lesions showed the same expression pattern with cervical lesions. These findings suggest that FGFR2IIIc plays important roles in carcinogenesis of both cervical cancer and endometrioid cancer. FGFR2IIIc may serve as a novel molecular target for uterus cancer therapy.